Search Results

Invivyd, Inc. announced that VYD222, a half-life extended investigational monoclonal antibody, shows continued in vitro neutralization activity in pseudovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants.

ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, announced new data demonstrating that its antibodies are exceptionally potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most dominantly circulating variants worldwide.

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.

ANEW MEDICAL, INC. announces that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW’s secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing, announced the launch of the first publicly available and free HiFi long-read variant frequency database with global representation.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, with support from The Michael J. Fox Foundation for Parkinson’s Research, conducted the world’s largest study on LRRK2 G2019S and uncovered new insights into the variant.

Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study in Nature Structural & Molecular Biology titled “Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination”.